Beijing Wantai Biological Pharmacy Enterprise Co., Ltd, a Chinese pharmaceutical company listed on the Shanghai Stock Exchange (SHA: 603392), has announced that the National Medical Products Administration (NMPA) has accepted for review the market approval filing for its innovative recombinant human papillomavirus (HPV) vaccine. This nine-valent vaccine, which targets HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58, has been co-developed with Xiamen University, potentially offering a broader spectrum of protection against HPV-related diseases.
Currently, the only marketed nine-valent HPV vaccine in China is MSD’s Gardasil 9, with Chongqing Zhifei Biological Co., Ltd (SHE: 300122) serving as its agent. The acceptance of Wantai’s filing by the NMPA signifies a step forward in the diversification of HPV vaccine options within the Chinese market.- Flcube.com
